NCT03808610 Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia Status TERMINATED Phase PHASE1/PHASE2
NCT03805932 Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03798678 CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT03795571 Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL Status UNKNOWN Phase PHASE1
NCT03785184 A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy Status WITHDRAWN Phase PHASE2
NCT03773107 LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma Status COMPLETED Phase PHASE1/PHASE2
NCT03769818 Role of Dexamethasone for Erector Spinae Plane Block in Patients Undergoing Total Abdominal Hysterectomy Status COMPLETED Phase NA
NCT03767920 Role of Dexamethasone in Transversus Abdominis Plane Block After Cesarean Section Status COMPLETED Phase NA
NCT03765541 Dexamethasone in Refractory or First Relapsed Acute Myeloid Leukemia Status TERMINATED Phase PHASE3
NCT03763760 High-Dose Steroid for Hip Arthroplasty Patients Expected to Have Postoperative Pain Status COMPLETED Phase PHASE4
NCT03763734 High-Dose Steroid for Knee Arthroplasty Patients Expected to Have Postoperative Pain Status COMPLETED Phase PHASE4
NCT03763162 Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03757715 Regional Anesthesia to Reduce Opioid Use Following Functional Endoscopic Sinus Surgery Status COMPLETED Phase PHASE4
NCT03756896 Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT03742297 Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years Status ACTIVE_NOT_RECRUITING Phase PHASE3